FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Anastasia Ivanova

Research Profile

Concepts & Ideas

Procedures

Activities & Behaviors

Chemicals & Drugs

Disorders

Geographic Areas

North Carolina

Co-author Network

Publications

TOP 3
Laura Raftery; Joel E Tepper; Mebea Aklilu; Stephen A Bernard; A. William Blackstock; Janine M Davies; Richard M Goldberg; Anastasia Ivanova; Bert H O'Neil
A Two-cohort Phase I Study of Weekly Oxaliplatin and Gemcitabine, Then Oxaliplatin, Gemcitabine, and Erlotinib During Radiotherapy for Unresectable Pancreatic Carcinoma.
Anastasia Ivanova; Roy Tamura
Letter to the editor.
Anastasia Ivanova; Changfu Xiao; Yevgen Tymofyeyev
Two-stage designs for Phase 2 dose-finding trials.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Anastasia Ivanova (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Laura Raftery; Joel E Tepper; Mebea Aklilu; Stephen A Bernard; A. William Blackstock; Janine M Davies; Richard M Goldberg; Anastasia Ivanova; Bert H O'Neil
A Two-cohort Phase I Study of Weekly Oxaliplatin and Gemcitabine, Then Oxaliplatin, Gemcitabine, and Erlotinib During Radiotherapy for Unresectable Pancreatic Carcinoma.
American journal of clinical oncology 2013;36(3):250-3.
2013: Anastasia Ivanova; Roy Tamura
Letter to the editor.
Journal of biopharmaceutical statistics 2013;23(3):709-10.
2012: Anastasia Ivanova; Changfu Xiao; Yevgen Tymofyeyev
Two-stage designs for Phase 2 dose-finding trials.
Statistics in medicine 2012;31(24):2872-81.
2012: Lisa A Carey; Wing-Keung Chiu; Francisco J Esteva; Madlyn Ferraro; Andres Forero-Torres; Katherine A Hoadley; Timothy J Hobday; Anastasia Ivanova; Minetta C Liu; Cynthia X Ma; Paul Kelly Marcom; Erica L Mayer; Charles M Perou; Mothaffar F Rimawi; Hope S Rugo; Anna Maria Storniolo; Philip S Bernard; Emily Burrows; Antonio C Wolff; Eric P Winer
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(21):2615-23.
2012: Matthew C Foster; Anastasia Ivanova; Kristy L Richards; Chirag Amin; Nathan D Barr; Wingkeung Michael Chiu; Hendrik W van Deventer; Peter M Voorhees; Jennifer Whitman; Thomas Shea
A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
Leukemia & lymphoma 2012;53(7):1331-7.
2011: Anastasia Ivanova; Bahjat F Qaqish; David A Schoenfeld
Optimality, sample size, and power calculations for the sequential parallel comparison design.
Statistics in medicine 2011;30(23):2793-803.
2011: Hanna Sanoff; Thomas E Stinchcombe; Christine M Walko; Larry Buie; Wing-Keung Chiu; Janine M Davies; William Irvin; Anastasia Ivanova; Kimberly Keller; Bert O Neil; Elizabeth Dees
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.
Investigational new drugs 2011;29(5):978-83.
2011: Janine M Davies; Nirav S Dhruva; Christine M Walko; Mark A Socinski; Stephen Bernard; D Neil Hayes; William Y Kim; Anastasia Ivanova; Kimberly Keller; Layla R Hilbun; Michael Chiu; Elizabeth Dees; Thomas E Stinchcombe
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Lung cancer (Amsterdam, Netherlands) 2011;71(2):151-5.
2011: Hanna Sanoff; Janine Davies; Christine M Walko; Larry Buie; Wing-Keung Chiu; Anastasia Ivanova; Bert O Neil; Thomas E Stinchcombe; Kimberly Keller; Elizabeth Dees
Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Investigational new drugs 2011;29(1):131-6.
2010: William Irvin; Robert Z Orlowski; Wing-Keung Chiu; Lisa A Carey; Frances A Collichio; Philip S Bernard; Inge J Stijleman; Charles Perou; Anastasia Ivanova; Elizabeth Dees
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
Clinical breast cancer 2010;10(6):465-70.
2010: Bert H O'Neil; Laura Raftery; Benjamin F Calvo; A Bapsi Chakravarthy; Anastasia Ivanova; Michael O Myers; Hong Jin Kim; Emily Chan; Paul E Wise; Laura S Caskey; Stephen A Bernard; Hanna Sanoff; Richard M Goldberg; Joel E Tepper
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
Clinical colorectal cancer 2010;9(2):119-25.
2009: Swaroop S Singh; Diana C Mehedint; O Harris Ford; D Antony Jeyaraj; Elena A Pop; Susan J Maygarden; Anastasia Ivanova; Rameela Chandrasekhar; Gregory E Wilding; James L Mohler
Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis.
The Prostate 2009;69(15):1603-10.
2009: Anastasia Ivanova; Ken Liu; Ellen Snyder; Duane Snavely
An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding study.
Statistics in medicine 2009;28(24):2941-51.
2009: Anastasia Ivanova; Se Hee Kim
Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.
Biometrics 2009;65(1):307-15.
2009: Anastasia Ivanova; Michael Murphy
An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations.
Journal of biopharmaceutical statistics 2009;19(2):247-55.
2008: Elizabeth Dees; Bert O Neil; Celeste Lindley; Frances A Collichio; Lisa A Carey; Jason Collins; William J Riordan; Anastasia Ivanova; Dixie Esseltine; Robert Z Orlowski
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Cancer chemotherapy and pharmacology 2008;63(1):99-107.
2008: Mary Ann Knovich; Dora Il'yasova; Anastasia Ivanova; István Molnár
The association between serum copper and anaemia in the adult Second National Health and Nutrition Examination Survey (NHANES II) population.
The British journal of nutrition 2008;99(6):1226-9.
2008: Anastasia Ivanova; James A Bolognese; Inna Perevozskaya
Adaptive dose finding based on t-statistic for dose-response trials.
Statistics in medicine 2008;27(10):1581-92.
2008: Ibrahim Salama; Anastasia Ivanova; Bahjat F Qaqish
Efficient generation of constrained block allocation sequences.
Statistics in medicine 2008;27(9):1421-8.
2008: Dora Il'yasova; Anastasia Ivanova; Jason D Morrow; Matteo Cesari; Marco Pahor
Correlation between two markers of inflammation, serum C-reactive protein and interleukin 6, and indices of oxidative stress in patients with high risk of cardiovascular disease.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2008;13(1):41-51.
2008: Sarah Zohar; Qing Lian; Vincent Levy; Ken Cheung; Anastasia Ivanova; Sylvie Chevret
Quality assessment of phase I dose-finding cancer trials: proposal of a checklist.
Clinical trials (London, England) 2008;5(5):478-85.
2007: Wjatschesslaw A Wlassoff; Craig D Albright; Michael S Sivashinski; Anastasia Ivanova; Jacob G Appelbaum; Rudolph I Salganik
Hydrogen peroxide overproduced in breast cancer cells can serve as an anticancer prodrug generating apoptosis-stimulating hydroxyl radicals under the effect of tamoxifen-ferrocene conjugate.
The Journal of pharmacy and pharmacology 2007;59(11):1549-53.
2007: Thomas E Stinchcombe; Mark A Socinski; Christine M Walko; Bert O Neil; Frances A Collichio; Anastasia Ivanova; Hua Mu; Michael J Hawkins; Richard M Goldberg; Celeste Lindley; E Claire Dees
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Cancer chemotherapy and pharmacology 2007;60(5):759-66.
2006: Anastasia Ivanova
Escalation, group and A + B designs for dose-finding trials.
Statistics in medicine 2006;25(21):3668-78.
2006: Hanna Sanoff; Gretchen Kimmick; Elizabeth Dees; Frances A Collichio; Lisa Gatti; Lynda Sawyer; Anastasia Ivanova; Lynn Dressler; Mark Graham II; Lisa A Carey
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Clinical breast cancer 2006;7(3):237-43.
2006: Jane C Schroeder; Jeannette T Bensen; L Joseph Su; Merle H Mishel; Anastasia Ivanova; Gary J Smith; Paul A Godley; Elizabeth T H Fontham; James L Mohler
The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes.
The Prostate 2006;66(11):1162-76.
2006: Anastasia Ivanova; Kai Wang
Bivariate isotonic design for dose-finding with ordered groups.
Statistics in medicine 2006;25(12):2018-26.
2006: Shannon S Carson; John P Kress; Jo E Rodgers; Ajeet G Vinayak; Stacy Campbell-Bright; Joseph Levitt; Sharya Bourdet; Anastasia Ivanova; Ashley Henderson; Anne S Pohlman; Lydia Chang; Preston B Rich; Jesse Hall
A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients.
Critical care medicine 2006;34(5):1326-32.
2006: Mark A Socinski; Anastasia Ivanova; Kamal Bakri; J Wall; Maria Q Baggstrom; Thomas A Hensing; Andrea Mears; Maureen Tynan; J Beaumont; Amy Peterman; Harvey B Niell
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):104-9.
2005: Thomas Konrad; Daniel L. Howard; Lloyd J Edwards; Anastasia Ivanova; Timothy S Carey
Physician-patient racial concordance, continuity of care, and patterns of care for hypertension.
American journal of public health 2005;95(12):2186-90.
2005: D Stephen Coad; Anastasia Ivanova
Sequential urn designs with elimination for comparing K > or =3 treatments.
Statistics in medicine 2005;24(13):1995-2009.
2005: Anastasia Ivanova; Bahjat F Qaqish; Michael J Schell
Continuous toxicity monitoring in phase II trials in oncology.
Biometrics 2005;61(2):540-5.
2005: Anastasia Ivanova; Robert C Barrier; Vance W Berger
Adjusting for observable selection bias in block randomized trials.
Statistics in medicine 2005;24(10):1537-46.
2005: D Stephen Coad; Anastasia Ivanova
The use of the triangular test with response-adaptive treatment allocation.
Statistics in medicine 2005;24(10):1483-93.
2005: Robert Z Orlowski; Peter M Voorhees; Reynaldo A Garcia; Melissa D Hall; Fred J Kudrik; Tammy Allred; Anandhi R Johri; Paul E Jones; Anastasia Ivanova; Hendrik W van Deventer; Don A Gabriel; Thomas C Shea; Beverly S Mitchell; Julian Adams; Dixie Esseltine; Elizabeth Trehu; Marie Green; Mary Jo Lehman; Susan Natoli; Jason M Collins; Celeste Lindley; Elizabeth Dees
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Blood 2005;105(8):3058-65.
2005: Kai Wang; Anastasia Ivanova
Two-dimensional dose finding in discrete dose space.
Biometrics 2005;61(1):217-22.
2004: Michael D Peck; Mary Kessler; Bruce A Cairns; Yih-Harn Chang; Anastasia Ivanova; Wesley Schooler
Early enteral nutrition does not decrease hypermetabolism associated with burn injury.
The Journal of trauma 2004;57(6):1143-8; discussion 1148-9.
2004: Dora Il'yasova; Jason D Morrow; Anastasia Ivanova; Lynne E Wagenknecht
Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane.
Annals of epidemiology 2004;14(10):793-7.
2004: Anastasia Ivanova; Kai Wang
A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
Statistics in medicine 2004;23(12):1861-70.
2003: Anastasia Ivanova
A new dose-finding design for bivariate outcomes.
Biometrics 2003;59(4):1001-7.
2003: Vance W Berger; Anastasia Ivanova; MARIA KNOLL
Minimizing predictability while retaining balance through the use of less restrictive randomization procedures.
Statistics in medicine 2003;22(19):3017-28.
2003: Gary G Schwartz; Dora Il'yasova; Anastasia Ivanova
Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III.
Diabetes care 2003;26(2):468-70.
2003: Anastasia Ivanova; Aliakbar Montazer-Haghighi; Sri Gopal Mohanty; Stephen D Durham
Improved up-and-down designs for phase I trials.
Statistics in medicine 2003;22(1):69-82.
2002: Anastasia Ivanova
Traditional design does not choose values around 33%.
Controlled clinical trials 2002;23(2):183.
2001: William F Rosenberger; Nigel Stallard; Anastasia Ivanova; C N Harper; M L Ricks
Optimal adaptive designs for binary response trials.
Biometrics 2001;57(3):909-13.
2001: Anastasia Ivanova; V W Berger
Drawbacks to integer scoring for ordered categorical data.
Biometrics 2001;57(2):567-70.
2000: Anastasia Ivanova; William F Rosenberger
A comparison of urn designs for randomized clinical trials of K > 2 treatments.
Journal of biopharmaceutical statistics 2000;10(1):93-107.
1998: V W Berger; T Permutt; Anastasia Ivanova
Convex hull test for ordered categorical data.
Biometrics 1998;54(4):1541-50.